Wednesday, February 10, 2010, 6:00am EST - Canadian Markets open in 3 hours and 30 minutes.
To create a watchlist or portfolio of shares, Sign-in or Register

Santarus Inc. (SNTS)

 On Feb 9: 3.70 USD   0.00 (0.00%)  
MORE ON SNTS
Quotes
HereSummary
Charts
News & Info
Company
Analyst Coverage
Ownership
Financials
Santarus, Inc. (NGM:SNTS) Delayed quote dataEdit
Last Trade: 3.70 USD
Trade Time: Feb 9
Change: 0.00 (0.00%)
Prev Close: 3.70
Open: N/A
Bid: N/A
Ask: 6.34 x 100
1y Target Est: 4.75
Day's Range: N/A - N/A
52wk Range: 1.05 - 5.82
Volume: 0
Avg Vol (3m): 697,211
Market Cap: 214.88M
P/E (ttm): N/A
EPS (ttm): -0.86
Div & Yield: N/A (N/A%)
Santarus Inc. (SNTS)
1d  5d  3m  6m  1y  2y  5y  max 
 Add SNTS to Portfolio   Download Data

HEADLINES
• SANTARUS INC Files SEC form 8-K, Other Events
EDGAR Online (Tue, Feb 2)
• SANTARUS INC Files SEC form 8-K, Other Events
EDGAR Online (Fri, Jan 15)
• Neutral on Santarus
Zacks.com (Wed, Jan 6)
• Santarus Receives $20 Million
Zacks.com (Wed, Dec 30)
• Santarus eyes Phase III trials for diarrhea drug
at MarketWatch (Wed, Dec 30)
• Santarus Submits IND for Phase III Clinical Testing of Rifamycin SV MMX in Travelers Diarrhea
Business Wire (Wed, Dec 30)
• 3 Stocks Ready to Roar
at Motley Fool (Wed, Dec 23)
• Santarus Receives Previously Announced $20 Million Milestone for FDA Approval of ZEGERID OTC
Business Wire (Tue, Dec 22)
• Santarus Lippert/Heilshorn Life Sciences Call scheduled for 10:30 am ET today
Vcall (Tue, Dec 15)
• Santarus Announces Webcast Presentation at the Lippert/Heilshorn Life Sciences Virtual Conference
Business Wire (Mon, Dec 14)
• Santarus, JA Solar: Early Volume Plays
at TheStreet.com (Mon, Dec 7)
• SANTARUS INC Files SEC form 8-K, Other Events
EDGAR Online (Mon, Dec 7)
More Headlines for SNTS...
ANALYST
EPS Est (next year) (Dec-07) : -0.95
EPS Est (in 2 years) (Dec-08) : -0.47
Avg Rec (current)*: 2.3
PEG Ratio: N/A
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
Analyst Opinion - Estimates

BUSINESS SUMMARY
Santarus, Inc., a specialty pharmaceutical company, engages in the acqusition, development, and commercialization of proprietary products and therapies that treat gastrointestinal diseases and disorders, including gastroesophageal reflux disease (...

Full Company Profile

Add to My Portfolio Add to Portfolio    Email to a Friend Email to a Friend
Get Summary for Another Symbol:
Symbol Lookup
• Latest News • Canadian Indices